Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate

MT newswire2026/09/14 13:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

09:09 AM EDT, 09/14/2026 (MT Newswires) -- Janux Therapeutics (JANX) said Monday the first participant has been dosed in a phase 1 clinical trial assessing its novel CD28 co-stimulatory bispecific, JANX-013, in healthy volunteers. Designed to target prostate-specific membrane antigen, JANX-013 is a tumor-activated immune modulator intended to be developed in combination with JANX-007, Janux's PSMA-targeted CD3 T-cell engager candidate, in patients with metastatic castration-resistant prostate cancer. The company said the combination aims to further enhance the durability of anti-tumor immune responses through tumor-restricted CD28 co-stimulation.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bank of America CEO Brian Moynihan stated that the bank's trading revenue this quarter will be "relatively flat" compared to the third quarter last year, in contrast to the surge in revenue experienced on Wall Street during the first half of this year. He also expects investment banking fees to be between $1.6 billion and $1.8 billion, falling short of the market's expectation of nearly $2 billion.

华尔街见闻•2026/09/14 18:51

10-Year Treasury Yield Touches 5%, Pushed by Oil Surge-- WSJ

Dow Jones•2026/09/14 18:46

8 Major Banking Institutions Issue Strong Statement Against Clarity Act, the Bullish Cryptocurrency Act

BitcoinSistemi•2026/09/14 18:39

Brian Moynihan Says Investment Banking Revenues Are Down at BofA -- WSJ

Dow Jones•2026/09/14 18:39